4.3 Review

HIV-1 superinfection

Journal

CURRENT OPINION IN INFECTIOUS DISEASES
Volume 25, Issue 1, Pages 42-50

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e32834ef5af

Keywords

dual infection; HIV-1; superinfection

Funding

  1. Gilead Sciences
  2. Merck Sharpe Dohme
  3. Boehringer Ingelheim
  4. ViiV Pharmaceuticals
  5. Janssen (a division of Johnson Johnson)
  6. Pfizer
  7. Abbott

Ask authors/readers for more resources

Purpose of review This review describes the nature and frequency of HIV-1 superinfection and provides advice regarding counselling of patients in accordance with national guidelines. Recent findings Recent studies have demonstrated conflicting results, from no superinfection to an incidence of over 18%. We discuss the difficulties comparing studies due to population and methodological differences. Summary HIV-infected individuals should be counselled that there is risk of superinfection at all stages of HIV, but this is unlikely to be clinically significant unless transmission of resistance occurs. The risk may be as high as the risk of new incident infection in the presence of on-going exposure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available